Double blind-randomized controlled trial for the efficacy of third line H. pylori eradication therapy between sitafloxacin-including regimen and sitafloxacin and metronidazole-including regime
Phase 3
- Conditions
- H. pylori-positve patients after the 2nd line eradication failure
- Registration Number
- JPRN-UMIN000006483
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with allergy for quinolones 2. Patients with allergy for PPIs 3. Patients with severe liver injury and/or severe renal damage 4. Pregnancy or possible pregnancy 5. Patients who were recognized as inappropriate for entry
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of H. pylori eradication
- Secondary Outcome Measures
Name Time Method MIC of STFX, FIC index of the interaction between STFX and MNZ, gyaA mutation